Literature DB >> 24941929

Unanswered questions in the management of axial spondyloarthritis: an opinion piece.

Xenofon Baraliakos, Atul Deodhar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24941929     DOI： 10.1007/s10067-014-2740-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  46 in total

1.  Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?

Authors:  Howard Lee
Journal:  AAPS J       Date:  2013-10-11       Impact factor: 4.009

2.  High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study).

Authors:  Federico Navarro-Sarabia; José L Fernández-Sueiro; Juan C Torre-Alonso; Jordi Gratacos; Rubén Queiro; Carlos Gonzalez; Eduardo Loza; Luis Linares; Pedro Zarco; Xavier Juanola; José Román-Ivorra; Emilio Martín-Mola; Raimon Sanmartí; Juan Mulero; Gema Diaz; Yolanda Armendáriz; Eduardo Collantes
Journal:  Rheumatology (Oxford)       Date:  2011-06-23       Impact factor: 7.580

3.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.

Authors:  M Rudwaleit; D van der Heijde; R Landewé; J Listing; N Akkoc; J Brandt; J Braun; C T Chou; E Collantes-Estevez; M Dougados; F Huang; J Gu; M A Khan; Y Kirazli; W P Maksymowych; H Mielants; I J Sørensen; S Ozgocmen; E Roussou; R Valle-Oñate; U Weber; J Wei; J Sieper
Journal:  Ann Rheum Dis       Date:  2009-03-17       Impact factor: 19.103

Review 4.  Wnt pathway and IL-17: novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG axis.

Authors:  Dimitrios Daoussis; Andrew P Andonopoulos; Stamatis-Nick C Liossis
Journal:  Semin Arthritis Rheum       Date:  2008-12-18       Impact factor: 5.532

5.  The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis.

Authors:  Nigil Haroon; Robert D Inman; Thomas J Learch; Michael H Weisman; MinJae Lee; Mohammad H Rahbar; Michael M Ward; John D Reveille; Lianne S Gensler
Journal:  Arthritis Rheum       Date:  2013-10

6.  Bisphosphonates vs infliximab in ankylosing spondylitis treatment.

Authors:  Ombretta Viapiana; Davide Gatti; Luca Idolazzi; Elena Fracassi; Silvano Adami; Sonila Troplini; Maria Rosaria Povino; Maurizio Rossini
Journal:  Rheumatology (Oxford)       Date:  2013-09-24       Impact factor: 7.580

7.  Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis.

Authors:  Xenofon Baraliakos; Hildrun Haibel; Joachim Listing; Joachim Sieper; Jürgen Braun
Journal:  Ann Rheum Dis       Date:  2013-03-16       Impact factor: 19.103

8.  2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis.

Authors:  J Braun; R van den Berg; X Baraliakos; H Boehm; R Burgos-Vargas; E Collantes-Estevez; H Dagfinrud; B Dijkmans; M Dougados; P Emery; P Geher; M Hammoudeh; R D Inman; M Jongkees; M A Khan; U Kiltz; Tk Kvien; M Leirisalo-Repo; W P Maksymowych; I Olivieri; K Pavelka; J Sieper; E Stanislawska-Biernat; D Wendling; S Ozgocmen; C van Drogen; Bj van Royen; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2011-06       Impact factor: 19.103

9.  A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.

Authors:  Dae Hyun Yoo; Pawel Hrycaj; Pedro Miranda; Edgar Ramiterre; Mariusz Piotrowski; Sergii Shevchuk; Volodymyr Kovalenko; Nenad Prodanovic; Mauricio Abello-Banfi; Sergio Gutierrez-Ureña; Luis Morales-Olazabal; Michael Tee; Renato Jimenez; Omid Zamani; Sang Joon Lee; HoUng Kim; Won Park; Ulf Müller-Ladner
Journal:  Ann Rheum Dis       Date:  2013-05-16       Impact factor: 19.103

10.  The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial.

Authors:  Jürgen Braun; Xenofon Baraliakos; Kay-Geert A Hermann; Atul Deodhar; Désirée van der Heijde; Robert Inman; Anna Beutler; Yiying Zhou; Stephen Xu; Benjamin Hsu
Journal:  Ann Rheum Dis       Date:  2013-05-03       Impact factor: 19.103
View more
  1 in total

1.  Comment on "treat-to-target in spondyloarthritis: implications for clinical trial designs".

Authors:  Daniel Wendling; Clément Prati
Journal:  Drugs       Date:  2014-09       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.